On March 10, the U.S. Food and Drug Administration (FDA) approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma. Read more.
FDA approves first therapy for high-risk neuroblastoma
Share
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
